Abstract-We investigated 3 hypotheses: (1) N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in patients with hypertension, (2) NT-proBNP is associated with blood pressure variability, and (3) NT-proBNP predicts benefit from antihypertensive regimens. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) randomized a subset of 6549 patients at risk with no history of coronary heart disease to either atenolol-based or amlodipine-based blood pressure-lowering treatment. During 5.5 years of follow-up, 485 cardiovascular disease cases accrued and were matched with 1367 controls. Baseline and 6-month in-trial NT-proBNP were measured. The results show that NT-proBNP improves cardiovascular disease risk prediction beyond established predictors, continuous net reclassification improvement of 22.3% (P<0.0001). Furthermore, a 1-mm Hg increase in the SD of systolic blood pressure was associated with 2% higher baseline NT-proBNP in a multivariable regression analysis (P<0.0001). However, NT-proBNP predicted cardiovascular disease risk independently of blood pressure variation (odds ratio per SD increase in log NT-proBNP 1.24; 95% confidence interval, 1.06-1.45; P=0.007). Atenolol-based treatment led to a 69.6% increase in NT-proBNP at 6 months (P<0.0001). In contrast, amlodipine-based treatment reduced NT-proBNP by 36.5% (P<0.0001). Amlodipine recipients who achieved a 6-month NT-proBNP below the median (61 pg/mL) were at lower risk of cardiovascular disease when compared with those who did not (odds ratio, 0.58; 95% confidence interval, 0.37-0.91) after adjustment for confounders inclusive of baseline NT-proBNP and achieved blood pressure. If confirmed, these novel results suggest that NT-proBNP, as well as aiding cardiovascular disease risk assessment, may also help assess the efficacy of specific antihypertensive regimens. Further relevant studies seem warranted. 
N atriuretic peptides, such as the B-type natriuretic peptide (BNP) hormone and the inactive N-terminal BNP fragment (NT-proBNP), are produced by cardiac tissue in response to volume overload and ventricular wall distension and may be elevated after myocardial ischemia, hypoxia, and fibrosis. 1 There is evidence of complex neurohormonal and inflammatory signaling underpinning natriuretic peptide synthesis; endothelin-1 and angiotensin-II are considered potent regulators. 2 As such, ischemic damage and most other cardiac abnormalities seem to increase circulating natriuretic peptides, 3 and circulating levels are positively associated with risk of cardiovascular disease (CVD). 4 There is increasing interest in the potential use of NT-proBNP for clinical stratification of CVD risk, [4] [5] [6] although questions about this potential use remain.
In addition to classical CVD risk prediction, the use of NT-proBNP as a surrogate marker for CVD risk during prophylactic drug treatments is of potential interest. We have previously shown that statin treatment has no effect on NT-proBNP. 4 However, there is evidence of a relationship between blood pressure (BP), BP variation (indicating arterial inelasticity and increased CVD risk), 7 and natriuretic peptide expression. Indeed, a recent small study showed that patients with hypertension and abnormal circadian BP variation have higher natriuretic peptide levels than those with normal variation. 8 Thus, changes in BP might be hypothesized to be associated with changes in natriuretic peptides. In patients with heart failure (HF), previous studies have suggested that the use of β-blockers might increase natriuretic peptides
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although not all data concur. 12 The reason for this increase in NT-proBNP is not clear, but it may be related to increased diastolic filling time. Whether antihypertensive medication has any effect on natriuretic peptides in patients with hypertension without HF, and whether any consequent change in NT-proBNP itself is associated with risk, beyond changes in BP, is presently unclear. These issues are important to clarify the potential clinical and academic uses of NT-proBNP as a reliable CVD risk marker.
We have recently established a nested case-control study from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) for investigating clinical use of biomarkers in stratifying CVD risk. 13 Using this resource, we aimed to investigate NT-proBNP and CVD risk prediction in patients with hypertension, whether NT-proBNP is associated with BP variability, and to what extent BP-lowering treatment (amlodipine or atenolol based) altered NT-proBNP and whether achieved on-treatment NT-proBNP independently predicted subsequent CVD risk.
Methods

Patients and Recruitment
The detailed ASCOT protocol has been published previously, 14 and further information is available at http://www.ascotstudy.org. The use of the ASCOT case-control study as an ancillary risk association study has been reported previously. 13 In brief, patients with hypertension, with ≥3 other risk factors for CVD but no history of prior myocardial infarction or currently treated angina, were eligible for enrolment in ASCOT-BP-lowering arm. In ASCOT-BP-lowering arm, in the United Kingdom and Ireland, 9098 patients were randomized to either amlodipine adding perindopril as required or atenolol adding bendroflumethiazide as required. Treatment was titrated to achieve <140/90 mm Hg (130/80 mm Hg in those with diabetes mellitus). Patients with total cholesterol ≥6.5 mmol/L could be randomized to an atorvastatin 10 mg daily arm or a placebo arm. Baseline characteristics of participants and primary outcomes of each arm of the trial have previously been reported. 14, 15 The study was performed in accordance with the Declaration of Helsinki. The protocol was ratified by central and regional ethics review boards in all relevant countries. Patients included in this study gave written informed consent to participate in the trial and to storage of samples for biomarker studies.
BPs throughout the study were measured using standardized techniques. At every visit (baseline, 6 weeks, 3 months, 6 months, and every 6 months thereafter) clinic BP was measured 3× in the sitting position after 5 minutes rest with a validated, semiautomated oscillometric device (Omron HEM-705CP; OMRON Healthcare, Kyoto, Japan).
14 All screening and in-study ECGs were read at a central ECG coding laboratory, for signs of left ventricular hypertrophy. 16 In addition, blood samples were obtained by venepuncture at study visits, and serum samples were stored at −80°C until the time of assay as previously detailed. 13 All events of fatal coronary heart disease (CHD), symptomatic nonfatal myocardial infarction, coronary revascularization, and fatal and nonfatal stroke occurring in the United Kingdom and Ireland during the ASCOT study period (median follow-up 5.5 years) between February 1998 and October 2005 were identified as cases. A UK and Ireland study, center-based nested case-control study, based on the ASCOT-BP-lowering arm cohort was used to determine the association of baseline NT-proBNP with subsequent events (Figure 1 ). For the purpose of the present study, those with any history of other CVDs (such as peripheral vascular disease, atrial fibrillation, stroke or transischemic attack, and HF) at screening visit were excluded. In the case-control analyses, 490 CVD events were confirmed. Controls were selected from the UK and Ireland ASCOT study population who were alive at the time the case was diagnosed and free from CVD in the study period. Up to 3 controls from the same risk-set were matched to each case by age (±1 year), sex, and study entry time ±90 days. In total, the 485 cases (355 CHDs and 130 strokes) were matched to 1367 controls ( Figure 1 ).
Laboratory Methods
C-reactive protein was measured via a routine clinical high sensitivity method. 13 NT-proBNP was measured by an electrochemiluminescence detection method on a clinically validated analyzer (Elecsys 2010; Roche diagnostics, Burgess Hill, United Kingdom) using monoclonal antibodies. Samples were run using the manufacturer's calibrators and controls. Low-control coefficient of variation was 5.6%, and high-control coefficient of variation was 6.6%. Both assays were performed in a single laboratory (University of Glasgow) on samples obtained at baseline and 6-month visits.
Statistical Methods
A crude analysis of the association between thirds of the distribution of NT-proBNP and baseline characteristics was explored by ANOVA tests or χ 2 tests. Risk associations were explored by conditional logistic regression (online-only Data Supplement). To examine the extent to which baseline log e NT-proBNP predicted CVD events, a baseline prediction model was devised comprising current smoking status, diabetes mellitus, baseline systolic BP (SBP), total cholesterol, and high-density lipoprotein-cholesterol, randomization groups and family history of CHD. This referent model was compared with a model including log e NT-proBNP. Discrimination of these models was assessed by the areas under the receiver operating characteristic curves using the nonparametric approach of DeLong et al. 17 Akaike information criterion and Bayes information criterion were used to assess global fit of these models with the observed data while penalizing for increased model complexity. Model calibration was assessed with the HosmerLemeshow goodness-of-fit test. We also performed likelihood-ratio tests to evaluate whether the global model fit improved after the addition of NT-proBNP. In these analyses, NT-proBNP was treated as a continuous variable. We also computed the net reclassification improvement as a continuous net reclassification improvement and an integrated discrimination improvement analysis. 18 Variability in visit-to-visit SBP was determined from the SD, and the coefficient of variation. To take account of the large BP reduction within the first 6 months, calculation of BP variability was based on readings from 6-month follow-up onward. The baseline NT-proBNP association with CVD independent of SBP variability (SBPV) in conditional logistic regression models (including and excluding SBPV) was explored using an established model developed in the full ASCOT-BP-lowering arm cohort. 7 SBP observations between visits at 6 and 30 months in trial were used to explore the association among baseline NT-proBNP, SBPV, and risk of CVD events after 30 months.
Effects of BP treatment on NT-proBNP were explored on subjects who had both NT-proBNP readings at baseline and at 6 months. A nonparametric Wilcoxon Mann-Whitney test was used to compare the 2 sample medians and Wilcoxon signed-rank test for paired data. Sensitivity analyses were performed on data restricted to those who were on monotherapy treatment of either atenolol or amlodipine during the first 6 months of study. We also examined the effects of achieved NT-proBNP on CVD events using conditional logistic regression models.
A 2-sided P<0.05 was considered statistically significant. All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC) and STATA version 12 (STATA Corporation, College Station, TX).
Results
Baseline Cohort Characteristics
During a median follow-up period of 5.5 years (interquartile range, 5.0-6.0) a total of 1852 cases and controls were eligible for inclusion in these analyses. Of these, 134 were excluded for missing values of baseline NT-proBNP or covariates used in the models ( Figure 1 ). Mean age in the study population was 64.7±7.7 years, 84.7% were men and median NT-proBNP in the study population was 89 pg/mL. NT-proBNP showed broadly expected associations with baseline classical risk factors in cases and controls (Table 1) although those in the top third of the NT-proBNP distribution had a lower resting heart rate and were slight less likely to have a family history of CHD. Further, a higher proportion of those randomized to amlodipine fell into the top third of NT-proBNP at baseline (Table 1) . Results were no different when analyses were restricted to the controls only, and continuous correlations of NT-proBNP with classical risk factors were further assessed and showed broadly expected results (online-only Data Supplement).
Baseline NT-proBNP and Prediction of CVD Events in Follow-Up
There was no evidence of an interaction between baseline NT-proBNP and statin/placebo (interaction P=0.74) or atenolol-/amlodipine-based treatment (interaction P=0.14) on CVD events; associations of baseline NT-proBNP with CVD risk were similar in all treatment groups.
Addition of NT-proBNP to a prediction model containing classical CVD risk factors (age, sex, smoking status, diabetes mellitus, baseline SBP, total cholesterol, high-density lipoprotein-cholesterol, family history of CHD, as well as randomized BP treatment and randomized statin treatment), led to an increase in area under the areas under the receiver operating characteristic from 0.598 to 0.625 (P=0.01).
In subjects who experienced CVD events, addition of NT-proBNP improved the predicted probability of an event; a continuous reclassification net gain of +8.5%. In subjects who did not experience an event, there was a reclassification net gain of 13.8%. The continuous net reclassification improvement for the model, including NT-proBNP, over the model without NT-proBNP was, therefore, estimated to be 22.3% (P<0.0001), and absolute integrated discrimination improvement was 1.74% (P<0.0001). Model calibration was not substantially altered by addition of NT-proBNP (onlineonly Data Supplement).
Baseline NT-proBNP and SBPV
There was a strong positive association between baseline thirds of NT-proBNP and SBPV for a median of 12 visits (Table 2) . On average, a 1-mm Hg increase in SBPV was associated with 2% higher baseline NT-proBNP in a multiple regression analysis (P<0.0001).
Baseline NT-proBNP was a significant predictor of CVD events in a model including only cases (and corresponding controls) occurring after 30 months of follow-up (odds ratio per SD increase in log NT-proBNP, 1.24; 95% confidence interval, 1.06-1.45; P=0.007 adjusting for variables included in Table 2 ). NT-proBNP remained significantly associated with risk with additional adjustment for SBPV in this model (odds ratio, 1.23; 95% confidence interval, 1.04-1.45; P=0.01).
BP-Lowering Treatment Effects on NT-proBNP
After 6 months of treatment, median NT-proBNP was reduced to 61 pg/mL (36.5% reduction) in the amlodipine-based treatment group, whereas it was increased to 134 pg/mL (69.6% increase) in the atenolol-based treatment group (P<0.0001 for value for comparison of change; Table 3 ). Stratifying by casecontrol status revealed no strong evidence that absolute change in NT-proBNP in the atenolol-or amlodipine-based treatment arms were different between cases and controls (P=0.75 and P=0.17, respectively; Table 3 ). These results were not substantially altered after adjusting for potential confounders (data not shown).
There were 160 and 233 subjects who were on monotherapy treatment of atenolol and amlodipine, respectively, during the first 6 months of study. Among the atenolol-based therapy group, multitherapy users tended to have a higher level of NT-proBNP at baseline (P<0.0001), but after 6-month treatment the change in NT-proBNP levels was not significantly different (P=0.91) between mono and multitherapies. For amlodipine-based therapy, there was no significant difference in NT-proBNP level at baseline (P=0.99) or for the change in NT-proBNP (P=0.10) comparing monotherapy versus multitherapy users (online-only Data Supplement). In the atenolol-based treatment group, the reduction in risk in those achieving median NT-proBNP of <134 pg/mL at 6 months was similar to those who did not achieve this threshold (Figure 2 ). However, in the amlodipine-based treatment group, those who achieved the median NT-proBNP at 6 months of ≤61 pg/mL were at reduced risk when compared with those who did not achieve this level (Figure 2 ) even adjusting for achieved SBP and low-density lipoprotein, as well as baseline NT-proBNP levels. This reduction in risk was also significant when using the atenolol-based treatment group as the referent. A borderline significant pattern also emerged when subjects were grouped by achieved SBP and achieved NT-proBNP although this model has less statistical power (online-only Data Supplement).
Discussion
In the ASCOT study, we report that amlodipine-based treatment decreased NT-proBNP >6 months, whereas atenolol-based treatment increased it. Among the amlodipine-based treatment group, an achieved NT-proBNP below the median was associated with a lower risk of subsequent CVD events. These observations are notable given that the amlodipine-based treatment randomized arm had fewer total cardiovascular events than the atenolol-based treatment randomized arm (hazard ratio, 0.84; 95% confidence interval, 0.78-0.90; P<0.0001). 15 In line with a growing body of evidence, 4-6 baseline NT-proBNP enhanced prediction of CVD events among hypertensive men and women without prior CVD. Thus, NT-proBNP may be a useful biomarker in the context of risk prediction in people with hypertension. Data from a small cohort study of patients with hypertension (median NT-proBNP of 82 pg/ mL; highly comparable with our cohort) previously reported that NT-proBNP is associated with mortality (n=40 outcomes) independent of a range of biomarkers, including ECG abnormalities. 19 Our data add to that study in terms of power, the use of a CVD end point, and the use of prediction metrics. The context of our finding in this regard is that natriuretic peptides Values are mean (SD) or n (%). BMI indicates body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SBP, systolic blood pressure. *Geometric mean (SD for log e ). †A total of 235 cases and 777 controls participated in lipid-lowering arm. by guest on August 30, 2017 http://hyper.ahajournals.org/ Downloaded from predictive properties probably relate to their ability to identify not only common silent pathologies underlying hypertension, such as subclinical left ventricular hypertrophy and ischemia, but also other conditions, such as reduced renal function 12, 20 ; NT-proBNP predicts CVD because of it being a useful integrated biomarker signal from a range of pathophysiological pathways. Whether cardiac biomarkers can help phenotype and apply a stratified medicine approach to treating patients with hypertension optimally remains to be seen. 21 It is of note that lowering of NT-proBNP in patients with HF is an established marker of improved outcome. 22 Therefore, it is plausible that more subtle absolute treatment-associated changes in NT-proBNP in individuals without HF (ie, primary prevention populations) may also predict benefit. Indeed previous data suggest that angiotensin-converting enzyme inhibitors may reduce natriuretic peptides by about a third in stable patients with HF, 12 and amlodipine lowers NT-proBNP to a similar relative extent in ASCOT, regardless of large absolute differences in NT-proBNP between studies. In contrast, atenolol, a β-blocker, has been previously reported in the Losartan Intervention For Endpoint (LIFE) study of participants with left ventricular hypertrophy to increase circulating BNP. 23 This effect was confirmed in a small clinical study, 24 where the augmentation index also rose on atenolol. The absolute and relative rise of NT-proBNP in response to atenolol in ASCOT was greater than that of BNP in those previous studies. Interestingly, multitherapy using thiazide (in addition to atenolol) or perindopril (in addition to amlodipine) seemed to have little effect on NT-proBNP change in addition to monotherapy. There may have been a small additional decrease in NT-proBNP in those receiving perindopril that we were underpowered to detect (P=0.10). The potential use of natriuretic peptides as a surrogate marker of drug effects for not just congestive HF, 25 but for a wider spectrum of cardiovascular end points, 26 requires further study after our findings. It had been suggested previously (eg, in the Heart Outcomes Prevention Evaluation [HOPE] trial of ramipril) 27 that reduction in BP does not always correspond to the expected CVD risk reduction. More recent data from meta-analysis of trials indicate that BP reduction does apparently explain the observed reduction in CVD risk on antihypertensives in general. 28, 29 There remains the possibility that within individuals, changes in biomarkers other than BP (such as NT-proBNP) yield information on risk reduction that might be useful to a clinician. In this case, a lowering of NT-proBNP is not necessarily a pleiotropic effect of the antihypertensive; rather it is a downstream marker of the biological effect of BP lowering. Indeed, our observation that BP variation is associated with NT-proBNP, but that NT-proBNP is associated with risk independently of BP variation (and of BP), suggests that NT-proBNP reflects risk from a variety of cardiac, vascular, and other pathways and serves as an excellent and potentially valuable integrated risk measure. Whether NT-proBNP reflects or improves prediction when compared with other BP metrics, such as central BP, 30 requires further study. Potential weaknesses of the study require consideration. Although we used a case-control design, case-control analyses result in only very small reduction in power in a study of this size. Our recent work that suggests the use of the case-control study provides very similar data to the whole cohort. 13, 31 Systolic and diastolic dysfunction was not adjusted for in our analyses. Despite this, echocardiography data collection is neither pragmatic nor cost-effective for large-scale CVD risk screening in primary prevention. Therefore, this does not Excluding the first 6-month measurements and postevent measurements in the SBP variability calculation. CV indicates coefficient of variation; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SBP, systolic blood pressure.
*Least squares means adjusted for mean in-trial SBP, age, sex, smoking status, total cholesterol, high-density lipoproteincholesterol, diabetes mellitus, randomized blood pressure treatment, randomized statin treatment, and family history of coronary heart disease.
by guest on August 30, 2017 http://hyper.ahajournals.org/ Downloaded from diminish the potential clinical relevance of our results in terms of prediction. The analysis reported by splitting the cohort by median achieved NT-proBNP is somewhat arbitrary; cutoffs based on medians are based on previous work on C-reactive protein 13 rather than any clinical criteria or guidelines. However, we have previously reported that the association of NT-proBNP with CVD risk seems to be continuous down to levels considered well within the normal range (≈30 pg/mL). 4 Analysis about changes in on-treatment NT-proBNP had only modest power and we cannot rule out the possibility of type 2 error. We also cannot rule out the possibility that some of the selection criteria imposed during ASCOT recruitment renders our results not generalizable to primary prevention patients who have hypertension and are generally prescribed antihypertensives, and accordingly our results should be considered hypothesis generating. We did not measure other natriuretic peptides, such as the active BNP and A-type NP hormones in this study. As such this study is an investigation of NT-proBNP as a biomarker and is limited in terms of the information it can give as to overall cardiac hormonal status. Nonetheless, these data have value in terms of simple CVD prediction and clinical responses to antihypertensive therapies. NT-proBNP was measured on stored serum samples, and although we cannot rule out the potential for differential sample degradation that biases our results for the long-term storage of this study, both of these markers seem fairly stable in long-term storage.
32
Perspectives
Previous work has debated the use of changes in the inflammatory marker C-reactive protein on statin treatment as a biomarker of treatment-derived benefit in addition to changes in low-density lipoprotein-cholesterol. 13, 31 The present data extend this line of investigation in assessing whether biomarkers, other than SBP, might be useful in assessing the CVD benefits of antihypertensives. We show that not only does NT-proBNP yield useful predictive information on patients with hypertension but also that its change may provide information on efficacy of amlodipine-based treatment independent of achieved SBP. However, atenolol-based treatment caused an increase in NT-proBNP, despite lowering SBP. Further study of the value of NT-proBNP in the CVD risk prediction setting in hypertension, both on and off BP treatment, seems warranted.
Acknowledgments
The sponsors of the study (Pfizer) had no role in the study design, data collection, data analyses, data interpretation, or writing of the report. The database was held by the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Executive Committee who had final responsibility for the decision to submit for publication. In relating NT-proBNP to risk of CVD the following adjustment models were used: model 1:
Sources of Funding
unadjusted (given that controls were age and sex matched); model 2 (modified Framingham CVD risk factors): adjusted for current smoking status, diabetes mellitus, family history of coronary heart disease, baseline systolic blood pressure (SBP), total cholesterol and HDL cholesterol, blood pressure and statin treatment randomized allocation; model 3 (extended CVD risk factors): as adjusted for model 2 plus body mass index (BMI), left ventricular hypertrophy, creatinine, glucose, educational attainment, log e C-reactive protein (CRP). 
